Related Experiment Video

Updated: Sep 12, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.6K

Structure-Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors

Anoopjit Singh Kooner1, Mariah Norman1, Igi Vilza2

  • 1Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, 63110, USA.

Chemmedchem
|August 8, 2025
PubMed

Insights

New imidazopyrazine compounds show promise for treating toxoplasmosis. These potent inhibitors target the essential TgCDPK1 enzyme, effectively blocking parasite growth in cellular models.

Area of Science:

  • Parasitology
  • Medicinal Chemistry
  • Structural Biology

Background:

  • Toxoplasmosis, caused by *Toxoplasma gondii*, is a significant threat to immunocompromised individuals.
  • Calcium-dependent protein kinases (CDPKs) in *T. gondii* regulate vital processes, with TgCDPK1 being crucial for parasite survival and infection.
  • TgCDPK1 is essential for *T. gondii* motility, invasion, and egress, making it a key therapeutic target.

Purpose of the Study:

  • To rationally design novel inhibitors targeting the TgCDPK1 enzyme.
  • To synthesize and evaluate new chemical series of TgCDPK1 inhibitors.
  • To identify lead compounds for the potential treatment of toxoplasmosis.

Main Methods:

  • Utilized existing X-ray cocrystal structures of pyrazolopyrimidine (PP) inhibitors bound to TgCDPK1 for structure-based drug design.
  • Designed six new chemical series of inhibitors based on structural insights.
  • Synthesized analogs from promising novel series and evaluated their inhibitory activity against TgCDPK1 and *T. gondii* growth in vitro.

Main Results:

  • Successfully designed and synthesized novel inhibitors targeting TgCDPK1.
  • Identified potent TgCDPK1 inhibitors from the imidazopyrazine chemical series.
  • Lead compounds 44 and 45 demonstrated significant efficacy in blocking *T. gondii* growth in cellular assays.

Conclusions:

  • The imidazopyrazine series represents a promising new class of inhibitors for TgCDPK1.
  • These novel compounds show potential for the development of effective treatments for toxoplasmosis.
  • Further development of these lead compounds could lead to a cure for toxoplasmosis.
Keywords:
calcium dependent protein kinase 1kinase inhibitorstructure‐based drug designtoxoplasmosis

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Efficient Construction of Drug-like Bispirocyclic Scaffolds Via Organocatalytic Cycloadditions of α-Imino γ-Lactones and Alkylidene Pyrazolones10:17

Efficient Construction of Drug-like Bispirocyclic Scaffolds Via Organocatalytic Cycloadditions of α-Imino γ-Lactones and Alkylidene Pyrazolones

Published on: February 7, 2019

7.0K

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Aromatic Hydrocarbon Cations: Structural Overview01:18

Aromatic Hydrocarbon Cations: Structural Overview

Cycloheptatriene is a neutral monocyclic unsaturated hydrocarbon that consists of an odd number of carbon atoms and an intervening sp3 carbon in the ring. The three double bonds in the ring correspond to 6 π electrons, which is a Huckel number, and therefore satisfies the criteria of 4n + 2 π electrons. However, the intervening sp3 carbon disrupts the continuous overlap of p orbitals. As a result, cycloheptatriene is not aromatic.
Removing one hydrogen from the intervening CH2 group...
3.0K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.4K
Diels–Alder Reaction Forming Bridged Bicyclic Products: Stereochemistry01:29

Diels–Alder Reaction Forming Bridged Bicyclic Products: Stereochemistry

Diels–Alder reactions between cyclic dienes locked in an s-cis configuration and dienophiles yield bridged bicyclic products.
4.8K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K